Background
Introduction
Renal dysfunction is a strong and independent predictor of prognosis in the general population, but also in patients with diabetes, hypertension, coronary artery disease, and heart failure [1] [2] [3] [4] [5] [6] [7] . The pathophysiology is multifactorial and associated with decreased renal perfusion, atherosclerosis and inflammation, endothelial dysfunction and neurohormonal activation [8] [9] [10] . We recently showed that in patients with cardiac dysfunction secondary to pulmonary hypertension, not only renal perfusion was a strongly associated with renal function impairment, but also venous congestion [11] . It is however unclear whether this observation is limited to those patients with reduced cardiac function and pulmonary hypertension, or may also be present in patients with a mixture of cardiovascular diseases with varying aetiologies and treatments. In addition, there is only limited data on the relationship between venous congestion, as estimated by central venous pressure (CVP) and the impact on prognosis, even in patients with and without heart failure. The studies that have been conducted are either small or include only non-invasive assessment of increased venous congestion, such as jugular venous pressure [12] [13] [14] [15] .
In the present study we therefore aimed to investigate the relationship between CVP, renal function and mortality in patients with a mixture of cardiovascular diseases with varying aetiologies and treatments.
Methods

Case Identification
Using the patient registration system of the University Medical Center Groningen, The Netherlands, all patients that underwent right heart catheterization between January 1, 1989, and December 31, 2006, were identified.
Data Extraction
Retrospective chart review was done to analyze characteristics of all patients that were identified during the electronic search. For each patient, date of birth, gender, race, and weight and height were collected. Comorbid conditions including hypertension, coronary artery disease, cardiac valve disease, congenital heart disease, history of stroke, hypercholesterolemia, and diabetes, medical treatment at the time of catheterization were also extracted for each patient. Furthermore, the reason for performing right heart catheterization was identified. The study was approved by the institutional review board.
Heart catheterization
Hemodynamic variables obtained during catheterization included systolic blood pressure (SBP, mmHg), diastolic blood pressure (DBP, mmHg), cardiac output (thermodilution, L/ min) and right atrial pressure as indicator of CVP (CVP, mmHg 
Renal function measurement
Serum creatinine at the day of catheterization was extracted. For the patients who did not have laboratory measurements on the day of catheterization, measurements obtained within 3 days prior to catheterization were taken as the baseline value. Of patients included in the study, 2282 (89%) had at least one serial creatinine measurement within 3 days of catheterization. Renal function was estimated as glomerular filtration rate by using the simplified modification of diet in renal disease equation ( Coresh et al [17] .
Mortality data
Survival status was determined using the electronic patient registration database of the University Medical Center Groningen. Follow up started directly after right heart catheterization. The primary endpoint consisted of death from any cause.
Statistical analysis
Data are given as mean ± standard deviation when normally distributed, as median and interquartile range when skewed distributed, and as frequencies and percentages for categorical variables. Associations between baseline variables were evaluated by means of 1-way ANOVA, the Kruskal-Wallis test, and χ 2 or Fisher exact tests, when appropriate. Two-sided P values were used, taking P < 0.05 to be statistically significant. CVP was divided into tertiles to assess relationships between baseline characteristics and CVP. A fractional polynomial parameterization of exposure was used to explore nonlinearity between different predictors and renal function. In this technique, each exposure value is expressed as a polynomial of degree greater than one (eg. quadratic, cubic, etc) , yielding an estimated model with multiple predictors (ie -separate predictors for the linear, quadratic, etc terms respectively). We used a Cox proportional hazards model to estimate hazard ratios (HR) with 95% CI. At first, in multivariate analysis, CVP was fitted into a stepwise multivariate Cox regression analysis on a continuous scale. In secondary analysis, CVP was fitted into the model and in multiple steps, the model was adjusted for other variables and parameters. The internal validity of the regression model was assessed by the bootstrap re-sampling technique [18] . For each of 100 bootstrap samples, the model was re-fitted and tested on the original sample to obtain a biascorrected estimate of predictive accuracy. Statistical analyses were performed using SPSS, Chicago version 12.0 and STATA, College Station, Texas, version 9.0.
Results
Baseline characteristics
A total of 3757 right heart catheterizations were carried out between 1989 and 2006. Of these, 2557 (68%) were first or only right heart catheterization of unique patients and formed the study population. Main reasons for right heart catheterization are shown in table 1. Aortic and mitral valve disorders accounted for 44% of indications, while in 16% acute or chronic heart failure was the predominant reason. Mean age was 59 ± 15 years, and 57% was male (Table 2 ). In the total study population, both mean cardiac index (2.9 ± 0.8 L/min/m 2 ) and mean CVP (5.9 ± 4.3 mmHg) were within the normal range. The distribution of CVP among the study population is shown in figure 1. Mean eGFR was moderately impaired: 65 ± 24 mL/ min/1.73m 2 .
The distribution of different factors over tertiles of CVP is shown in table 2. Most of the characteristics were equally distributed across tertiles of CVP, except for the highest tertile (CVP > 6 mmHg). Both cardiac output and cardiac index were significantly lower in the highest tertile compared to lower tertiles (P < 0.0001), corresponding to r = -0.259 (P < 0.0001) for the association between CVP and cardiac index. Furthermore, patients in the highest tertile were more frequently treated with ACEi/ARB, beta-blockers, diuretics and aldosterone antagonists. Prevalence of heart failure showed a trend towards increasing with higher tertiles of CVP (P = 0.0781), while also congenital heart disease was more prevalent in the highest tertile. Finally, Coronary artery disease 13
Pre transplantation (non-cardiac) 11
Rhythm disorders 5
Pulmonary hypertension 3
Congenital heart disease 2
Post heart transplantation 2
Other 6 eGFR was significantly lower in the highest tertile of CVP, compared to both lower tertiles (P < 0.001). Figure 1 shows the curvilinear relationship between CVP and eGFR in the total study population as obtained by fractional polynomial modelling. Estimated GFR showed a small increase when CVP increased from 1 to 6 mmHg. However, in CVP values above 6 mmHg, a steep decline is observed with increasing CVP values. This resulted in a partial correlation of r = 0.064, P =0.0218 in patients with CVP ≤ 6 mmHg, and r = -0.212, P < 0.0001 in patients with CVP > 6 mmHg (adjusted for age, gender and cardiac index). On a continuous scale, CVP was also significantly associated with eGFR (r = -0.110, P < 0.0001) after transformation.
Curvilinear fitting and the relationship between CVP and eGFR
Besides CVP, age (r = -0.438, P < 0.0001), gender (r = 0.137, P < 0.0001), and cardiac index (r = 0.249, P < 0.0001) were associated with eGFR. In addition, lower eGFR values were also found to be related with the use of any type of cardiovascular medication and a history of diabetes and hypertension. There was a significant interaction between CVP and cardiac index on the relationship with eGFR. The observed biphasic relationship between CVP and eGFR was most pronounced in patients with relatively normal cardiac index (Figure 2) .
In multivariate analysis, CVP remained associated with eGFR (r = -0.108, P < 0.0001, adjusted for covariates), which was confirmed by bootstrap analysis (Supplementary table 1) . After adjustment for the year of catheterization, the association between CVP and eGFR was numerically unchanged: r = -0.105, P < 0.0001. Excluding patients with a history of heart transplantation, who were likely to receive renal function compromising immunotherapy, CVP remained associated with eGFR (r = -0.108, P < 0.0001) in multivariate analysis. Including only patients without heart failure, similar associations were present (r = -0.080, P = 0.0034). Excluding both heart transplant recipients and heart failure patients, the association between CVP and eGFR remained (r = -0.079, P = 0.0042).
CVP and mortality
Mortality data was available in all patients, whereas time of death was available in 2424 (95%) of patients. Median follow-up among survivors was 10.7 years, and during follow up in total 741 (29%) of the patients died. Crude mortality ranged from 24%, in the lowest tertile, to 29% and 35% in the two highest tertiles of CVP (P = 0.0001 for trend). On a continuous scale, higher CVP levels were associated with impaired survival (HR = 1.05 per mmHg increase, 95% CI 1.04 to 1.07, P < 0.0001). Kaplan Meier survival curves for tertiles of CVP are shown in figure 3 , showing that especially patients with the highest CVP were at risk for increased mortality (HR for CVP > 6 mmHg versus ≤ 6 mmHg 1.49, 95% CI 1.26 to 1.76, P < 0.0001).
Baseline eGFR (HR = 1.09 per 10 mL/min/1.73m 2 decrease, 95% CI 1.05 to 1.13, P < 0.0001) and cardiac index (HR = 0.74 per L/min/m 2 , 95% CI 0.66 to 0.84, P < 0.0001) were also strong predictors of mortality. Other factors associated with reduced survival are shown in table 3. In stepwise multivariate Cox regression analysis, CVP remained significantly associated with reduced survival (HR = 1.03 per mmHg increase, 95% CI 1.01 to 1.05, P = 0.0032) (table 3) . Finally, we fitted a second model, adjusting CVP for other covariates (Supplementary Table 2 ). CVP remained an independent predictor of impaired survival (HR = 1.03 per mmHg increase, 95% CI 1.01 to 1.05, P = 0.0144). To account for the effects of changing therapy during the study inclusion time, we adjusted for the year of catheterization. This secondary analysis yielded similar results: HR = 1.03 per mmHg increase, 95% CI 1.00 to 1.05, P = 0.0207). Excluding patients with known heart failure and heart transplant recipients, CVP was still associated with mortality (HR = 1.03 per 5 mmHg increase, 95% CI 1.00 to 1.06, P = 0.0369). 
Discussion
The present study shows that increased CVP is associated with impaired renal function in a broad spectrum of cardiovascular patients who underwent right heart catheterization. In addition, the slope between CVP and impaired eGFR was steeper with relatively preserved cardiac function. Finally, an increased CVP was a strong and independent determinant of all cause mortality, which was especially observed in patients with a CVP above 6 mmHg.
There is only limited data on the relationship between increased CVP and renal impairment. Studies in animals have shown that raising renal venous pressure leads to a reduction in glomerular filtration, which was probably mediated by a decreased renal perfusion [19] . Renal vein constriction lead to a drop in glomerular filtration rate in rats [20] , while renal function decreased when renal vein pressure was increased in dogs, but only when cardiac output was reduced [21] . We recently showed that in patient with reduced cardiac function, secondary to pulmonary hypertension, increased CVP was strongly associated with renal impairment, especially when renal perfusion was already impaired [11] . Early studies on increased renal vein pressure in heart failure patients and animals showed a marked reduction in renal blood flow as well as water and salt excretion [22, 23] , but the effect on GFR was not uniform. One small report showed a strong relationship between CVP and renal blood flow in advanced heart failure [24].
Drazner et al reported that in patients with elevated jugular venous pressure on examination, serum creatinine was significantly higher [13] . In patients who underwent elective cardiac surgery, preoperative presence of high CVP was a strong predictor of the occurrence of acute renal injury, independent of the presence of low CO [25] .
However, especially in patients with preserved cardiac function, data regarding the relationship between CVP and renal function is scarce. Diastolic dysfunction, a disease characterised by elevated filling pressures, often co-exists with renal failure and vise versa [26] [27] [28] . Interestingly, a recent study showed that renal dysfunction is even more important in defining mortality risk in patients with preserved cardiac function compared to those with systolic dysfunction. [29, 30] . Our present study confirmed that increased CVP is an important risk factor for decreased renal function in patients with preserved and decreased cardiac function.
Curvilinear effect of CVP with eGFR
We observed a biphasic relationship between eGFR and increasing CVP. In the physiologic ranges of CVP, up to 6 mmHg, eGFR increases gradually. This subtle increase in eGFR may be a reflection of increased cardiac filling to preserve cardiac function by Frank-Starling mechanism (preload), and subsequent renal perfusion [31] . This gradual increase in eGFR was observed across the full spectrum of low to high cardiac index. We observed a decrease in eGFR when CVP rises above 6 mmHg. In these patients, the equilibrium between venous return, CO and CVP may have shifted towards a plateau phase or optimum, where CO is not further increased in response to higher CVP [32]. Higher CVP levels will then decrease renal perfusion pressure which will further impair eGFR. However, if higher CVP levels preserve CO, and despite this mechanism eGFR drops with higher CVP, this suggests that increased CVP may also exert an effect on GFR in this group of patients, independent of renal perfusion. Importantly, the relationship between CVP and GFR is bound to be bidirectional. Not only CVP may influence GFR, but even mildly impaired renal function may initiate salt and water retention, resulting in elevated filling pressures [33] . Due to the cross-sectional nature of our analysis, we were unable to investigate the cause effect associations, and our present analysis must be regarded as hypothesis generating.
CVP and eGFR in patients with and without cardiac dysfunction
Of particular interest is the interaction between cardiac index and CVP on eGFR. Patients who have a combination of reduced perfusion (cardiac index) and increased venous congestion (CVP) suffer from fluid overload and decreased organ perfusion, leading among other things to renal dysfunction. We showed that patients with high CVP levels often also have decreased cardiac index and reduced eGFR. Remarkably, CVP and cardiac index showed an interaction on the relationship with eGFR, with an even more pronounced relationship in patients with relatively normal cardiac index. This further strengthens the observation of a relationship between CVP and eGFR, which is not exclusively due to reduced cardiac systolic function. It also challenges the intuitive notion that fluid overload, although deleterious from a cardiovascular perspective, will invariably be beneficial from the point of view of preservation of renal function. As our analysis does not allow to dissect cause and effect relationships, however, it might also well be that the relatively normal cardiac index is maintained at the expense of the elevated CVP. In that case, apparently, such a renal hemodynamic profile does not translate into better renal function. Our present findings seem inconsistent with our earlier findings, showing that especially patients with reduced renal perfusion are prone to a detrimental effect of CVP on GFR [11] . However, we did not measure renal hemodynamics or renal function by clearance techniques, while also the population was entirely different. Furthermore, our previous study consisted of patients with much lower cardiac indices, all of which makes comparison difficult. Nevertheless, this inconsistency needs further addressing in future studies.
New therapeutic agents in especially acute heart failure, which are specifically targeted at improvement of cardiac function and reducing venous congestion have recently shown promising results regarding renal function. A substudy of the SURVIVE study, comparing levosimendan with dobutamine, showed that improvement of renal function was more pronounced in the group receiving levosimendan, despite the obvious positive inotropic effect of dobutamine [34] . The specific venodilatory effect observed with Levosimendan, with subsequent reduced central venous pressure may be the pathophysiologic mechanism, supporting a direct pathophysiologic link between CVP and renal impairment. [35] CVP and mortality Increased CVP and jugular venous pressure predispose to the development of heart failure in patients with cardiac dysfunction and have been associated with reduced survival in patients with heart failure [12, 13, 36] . Small studies have shown that invasive assessment of CVP is a predictor of cardiovascular outcome in patients with advanced heart failure [14, 15] . In other selected patients populations, such as patients who underwent fontan surgery or lung transplantation, higher central venous pressures were strong predictors of outcome [37, 38] . The prognostic importance of raised CVP in patients with normal cardiac function has not been reported before. We show that in a selected patient population, raised CVP remained a determinant of all-cause mortality, independent of cardiac function. This association with mortality was most prominent in patients with severely increased CVP, even after adjustment for other baseline characteristics. This finding was additive to the observation that higher CVP levels predispose to lower eGFR, which may influence survival by different mechanisms.
Clinical implications
Raised CVP is frequently observed in patients with and without reduced cardiac function, comprising of almost 20% of patients in the present patient population. Recognition of these patients is essential, while not only renal dysfunction is much more frequently observed, but also mortality risk rises with increasing CVP levels. Treatment to selectively lower CVP may be favourable to reduce symptoms and signs of congestion, improve GFR, and improve prognosis.
Limitations
The present study comprises of a selected patient population, who all had a specific indication for right heart catheterization. Patients undergoing right heart catheterization are prone to have higher right sided filling pressures, and the present observations may therefore not represent the general cardiovascular population. However, this is a large cohort study, with invasive cardiac function and CVP measurements across the full range. Second, this is a retrospective analysis, and no invasive data is available on renal blood flow and true GFR in these patients. Furthermore, it should be addressed that our study population had very different catheterization indications, medical history and medication regime, all of which could have influenced our results. In our study, the presence of heart failure was a clinical diagnosis, rather than related to reduced cardiac index on catheterization. Therefore, the prevalence of heart failure in our study is most likely underestimated. The relationship between increased CVP and renal perfusion has been observed in heart failure. However our present study is the first to show an independent effect of CVP on renal function. Finally, the retrospective nature of this study and the cross sectional design limit the ability to investigate the cause-effect relationship between renal impairment and increased CVP, that may actually mutually influence each other.
Conclusion
Increased CVP is associated with impaired renal function and independently related to all cause mortality in a broad spectrum of patients with cardiovascular disease. 
